Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI.
State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, China.
J Immunol. 2024 Jan 15;212(2):208-215. doi: 10.4049/jimmunol.2300480.
The gut microbiota, predominantly residing in the colon, is a complex ecosystem with a pivotal role in the host immune system. Dysbiosis of the gut microbiota has been associated with various diseases, and there is an urgent need to develop new therapeutics that target the microbiome and restore immune functions. This Brief Review discusses emerging therapeutic strategies that focus on oral delivery systems for modulating the gut microbiome. These strategies include genetic engineering of probiotics, probiotic-biomaterial hybrids, dietary fibers, and oral delivery systems for microbial metabolites, antimicrobial peptides, RNA, and antibiotics. Engineered oral formulations have demonstrated promising outcomes in reshaping the gut microbiome and influencing immune responses in preclinical studies. By leveraging these approaches, the interplay between the gut microbiota and the immune system can be harnessed for the development of novel therapeutics against cancer, autoimmune disorders, and allergies.
肠道微生物群主要存在于结肠中,是宿主免疫系统中具有关键作用的复杂生态系统。肠道微生物群的失调与各种疾病有关,因此迫切需要开发针对微生物组并恢复免疫功能的新疗法。本综述讨论了新兴的治疗策略,这些策略侧重于用于调节肠道微生物组的口服递送系统。这些策略包括益生菌的基因工程、益生菌-生物材料杂合体、膳食纤维以及微生物代谢物、抗菌肽、RNA 和抗生素的口服递送系统。在临床前研究中,经过工程设计的口服制剂已证明在重塑肠道微生物组和影响免疫反应方面具有广阔的前景。通过利用这些方法,可以利用肠道微生物组和免疫系统之间的相互作用,开发针对癌症、自身免疫性疾病和过敏的新型疗法。